A study shows that the silencing of GSX2 in pancreatic cancer cells resulted in a decrease in their proliferation, migration, and invasion, along with an increase in apoptosis and enhanced sensitivity to gemcitabine treatment [69]. This evidence concerns the gene GSX2 and pancreatic neoplasm.